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 Atypical hemolytic uremic syndrome 
(aHUS) is the triad of microangiopathic 
hemolytic anemia, thrombocytopenia, 
and acute renal failure. Advances in the 
past 15 years have shown aHUS to be a 
disorder of the alternative pathway of 
complement. Mutations in the comple-
ment-regulatory proteins factor H ( CFH ), 
factor I ( CFI ), and membrane cofactor 
protein ( CD46 ; MCP) and complement 
components factor B ( CFB ) and  C3 all 
result in complement overactivation. 1 
 Genetic screening of people with aHUS 
is now in mainstream clinical practice 
and provides important prognostic infor-
mation that guides clinical decision 
making. With increasing genetic analysis, 
genotype – phenotype correlations have 
emerged. For instance, in patients with 
mutations in  CFH there is a very poor 
prognosis; 60 – 70 % of patients die or reach 
end-stage renal failure within a year. In 
comparison, those with  CD46  mutations 
of podocyte-expressed proteins might 
yield a richer and more informative view 
of podocyte injury and loss. 
 Th e study of Fukuda  et al. 7 also raises 
the question of whether it is possible that, 
if initial therapy in human disease can limit 
early podocyte losses to less than a certain 
threshold, 13 inexorable progression to 
renal failure may be avoided. Conversely, 
if this is not possible, will it always be the 
case that aggressive enough angiotensin 
blockade (possibly, targeted to minimize 
urinary podocyte excretion) will be suffi  -
cient to preserve glomerular architectural 
stability, protect remnant podocytes, and 
assure long-term renal survival? 
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 Interpretation of genetic 
variants of uncertain 
significance in atypical 
hemolytic uremic syndrome 
 David  Kavanagh 1 and  Holly E.  Anderson 1  
 Mutations in complement proteins predispose to atypical hemolytic 
uremic syndrome (aHUS). Mutation screening in aHUS is challenging, 
because most of the disease-associated mutations are individually rare, 
and a significant proportion of variants consist of missense mutations 
of unknown significance. The definitive interpretation of a variant of 
unknown significance (VUS) is often dependent on a reliable functional 
assay too time-consuming to be used in a diagnostic screening service. 
Allied research groups have analyzed these VUSs in aHUS. 
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have a better outcome, with about 80 % 
remaining dialysis- independent. 2 The 
genetic defect can also predict the aHUS 
recurrence rate aft er renal transplanta-
tion. 3 Th e complement-regulatory defect 
in those with mutations in the membrane-
bound  CD46 is corrected by an allograft  
bearing wild-type  CD46 . In those 
with mutations in the serum complement 
regulators  CFI and  CFH , which are pro-
duced by the liver, a renal transplant does 
not correct the defect, so the recurrence 
rate is high. Th us genetic screening deter-
mines the suitability for isolated renal 
transplantation, combined liver – kidney 
transplantation, or the prophylactic use of 
eculizumab for transplantation. 
 Mutation screening in aHUS is chal-
lenging because most of the disease-
 associated mutations are individually rare 
( Figure 1 ). In most cases, interpretation of 
the functional signifi cance of nonsense 
mutations, large gene rearrangements, and 
frameshift  mutations is clear-cut. However, 
a signifi cant proportion of variants consist 
of missense mutations or potential splice-
site changes of uncertain biologic or clini-
cal relevance. Th ese variants of unknown 
signifi cance (VUSs) pose a challenge in 
reporting the genetic results. In these 
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settings numerous lines of  evidence may 
be used to assess the probability that a 
genetic variant may be relevant to disease. 
 Th is can be done by searching of locus-
specifi c databases for information on pre-
viously described genetic variants (for 
example, the FH aHUS Mutation Data-
base; www.fh -hus.org / ). Th e use of ethni-
cally matched controls is also a common 
mechanism to eliminate genetic variants 
as pathogenic. Species conservation anal-
ysis and  in silico prediction of the severity 
of amino acid changes or splice-site pre-
diction are also used. Th e defi nitive inter-
pretation of a VUS is oft en dependent on 
a reliable functional assay; however, these 
tests are too costly and time-consuming 
to be used in a diagnostic screening ser-
vice and usually rely on allied research 
groups. Th is has been the case for  CFH 
mutations in aHUS. 
 Factor H is composed of 20 complement 
control protein (CCP) modules. It is the 
most important fl uid-phase regulator of 
the alternative pathway. It competes with 
factor B for C3b binding, accelerates the 
decay of the C3 convertase into its compo-
nents, and acts as a cofactor for factor 
I-mediated proteolytic inactivation of C3b 
( Figure 1 ). Th ese functions are mediated 
through the N-terminal four CCPs 
(CCP1 – 4). Factor H also regulates com-
plement on host cells by binding to the 
glycosaminoglycans of endothelial cells 
and exposed basement membranes via its 
carboxyl-terminal domains (CCP19 – 20). 
 Th e majority of mutations in  CFH in 
aHUS are heterozygous and are located in 
exons encoding the C-terminal domain of 
the protein, which is responsible for medi-
ating complement protection of the cell 
surface ( Figure 1 ). Th ese mutations do not 
usually result in a quantitative defi ciency 
of factor H. Functional analysis of these 
mutations has revealed impaired comple-
ment regulation at the cell surface. 4,5 
 A few mutations in the N-terminal 
region of  CFH have been reported, and 
functional analysis has revealed that they 
are defective in their ability to control the 
alternative pathway both in the fl uid phase 
and on the cell surface. 6 
 VUSs have been described in the inter-
vening CCPs of factor H ( Figure 1 ), 
although a lack of functional analysis has 
resulted in an inability to predict their 
likely functional consequences. 
 Tortajada  et al. 7 (this issue) now pro-
vide compelling genetic and functional 
evidence suggesting that two genetic 
VUSs, I890 and L1007, previously 
reported in aHUS, may not play a role in 
disease pathogenesis. Th ey demonstrate 
that the frequency of the I890 and L1007 
variants is not signifi cantly diff erent in 
control and patient populations. Further 
genetic analysis demonstrated that these 
variants form part of an infrequent 
ancient  CFH haplotype in white people —
 probably of African origin, given the high 
frequency in sub-Saharan African and 
African-American populations. Th ese 
variants did not aff ect the factor H level 
in plasma. Functional analysis revealed 
that these variants in CCPs 15 (I890) and 
17 (L1007) did not aff ect binding to C3b. 
Th is would be consistent with previous 
mapping studies of factor H binding 8 and 
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 Figure 1  |  The interaction between complement factor H and C3b in the downregulation of the alternative pathway of complement . Factor H 
is composed of 20 CCP modules. The N-terminal modules (CCP1 – 4) bind to C3b and act as a cofactor for the factor I-mediated cleavage to the inactive 
iC3b. The C-terminal modules (CCP19 – 20) bind to C3b and glycosaminoglycans (GAG) on host cells to mediate cell surface protection. Genetic variants 
described in atypical hemolytic uremic syndrome cluster in CCP19 – 20, but can be seen throughout the molecule. In the study by Tortajada  et al ., 7  
functional analysis of variants in CCP15 (I890) and CCP17 (L1007) demonstrate no defect in complement regulation. CCP, complement control protein. 
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co-crystal structures of factor H with C3 
fragments. 9,10 In keeping with this, fl uid-
phase cofactor assays and cell-surface 
hemolytic assays do not reveal any defect 
in complement regulation. 
 Thus, although this study does not 
demo nstrate any functional signifi cance 
of these genetic variants, the importance 
of these results is not diminished. Publi-
cation bias will oft en see negative studies 
neglected and unpublished. Th is study is 
a fi ne example of the importance of the 
good negative study to the wider scien-
tifi c and medical communities. Using 
this information, genetic screening labo-
ratories will be able to provide more pre-
cise information as to the signifi cance of 
these VUSs. It also highlights the impor-
tance of revisiting past genetic data in the 
light of new evidence. People previously 
demonstrated to have these VUSs can 
now be reassured that these changes are 
not causative, while clinicians can modify 
their decisions in the sure knowledge 
that these variants are not pathogenic. 
Th e increasing amount of genetic data 
produced by the latest generation of 
sequencing technology oft en surpasses 
our ability to accurately interpret it. In 
this setting, the publication of well-
designed functional studies of VUSs, even 
when  nega tive such as that by Tortajada 
 et al. , 7 is vital to screening laboratories. 
 DISCLOSURE 
 The authors declared no competing interests. 
 ACKNOWLEDGMENTS 
 DK is a Wellcome Intermediate Clinical Fellow, 
and holds grants from Kidney Research UK 
and The Academy of Medical Sciences. 
 REFERENCES 
 1 .  Kavanagh  D ,  Goodship  T .  Genetics and 
complement in atypical HUS .  Pediatr Nephrol  2010 ; 
 25 :  2431 – 2442 . 
 2 .  Caprioli  J ,  Noris  M ,  Brioschi  S  et al.  Genetics of 
HUS: the impact of MCP, CFH, and IF mutations on 
clinical presentation, response to treatment, and 
outcome .  Blood  2006 ;  108 :  1267 – 1279 . 
 3 .  Kavanagh  D ,  Richards  A ,  Goodship  T ,  Jalanko  H . 
 Transplantation in atypical hemolytic uremic 
syndrome .  Semin Thromb Hemost  2010 ;  36 : 
 653 – 659 . 
 4 .  Ferreira  VP ,  Herbert  AP ,  Cortes  C  et al.  The bind-
ing of factor H to a complex of physiological 
polyanions and C3b on cells is impaired in atypical 
hemolytic uremic syndrome .  J Immunol  2009 ;  182 : 
 7009 – 7018 . 
 5 .  S á nchez-Corral  P ,  Gonz á lez-Rubio  C ,  Rodr í guez 
de C ó rdoba  S ,  L ó pez-Trascasa  M .  Functional 
analysis in serum from atypical Hemolytic Uremic 
Syndrome patients reveals impaired protection of 
host cells associated with mutations in factor H . 
 Mol Immunol  2004 ;  41 :  81 – 84 . 
 6 .  Pechtl  IC ,  Kavanagh  D ,  McIntosh  N  et al. 
 Disease-associated N-terminal complement 
factor H mutations perturb cofactor and decay-
accelerating activities .  J Biol Chem  2011 ;  286 : 
 11082 – 11090 . 
 7 .  Tortajada  A ,  Pinto  S ,  Mart í nez-Ara  J  et al. 
 Complement factor H variants I890 and L1007 
while commonly associated with atypical 
hemolytic uremic syndrome are polymorphisms 
with no functional significance .  Kidney Int  2012 ; 
 81 :  56 – 63 . 
 8 .  Schmidt  CQ ,  Herbert  AP ,  Kavanagh  D  et al. 
 A new map of glycosaminoglycan and C3b 
binding sites on factor H .  J Immunol  2008 ;  181 : 
 2610 – 2619 . 
 9 .  Morgan  HP ,  Schmidt  CQ ,  Guariento  M  et al. 
 Structural basis for engagement by complement 
factor H of C3b on a self surface .  Nat Struct Mol Biol 
 2011 ;  18 :  463 – 470 . 
 10 .  Wu  J ,  Wu  YQ ,  Ricklin  D  et al.  Structure of 
complement fragment C3b-factor H and 
implications for host protection by complement 
regulators .  Nat Immunol  2009 ;  10 :  728 – 733 . 
